蓝帆医疗股份有限公司第六届董事会第二十七次会议决议公告

Core Viewpoint - The company has decided to lower the conversion price of its convertible bonds, "蓝帆转债," from 12.00 RMB/share to 11.50 RMB/share, effective from August 15, 2025, due to the stock price performance and in accordance with relevant regulations [2][8][18]. Group 1: Board Meeting and Decision - The sixth board meeting of the company was held on August 14, 2025, where the proposal to adjust the conversion price was discussed and approved [1][2]. - The average trading price of the company's stock was 6.39 RMB/share over the twenty trading days prior to the meeting, and 6.32 RMB/share on the last trading day before the meeting [2][18]. - The board's decision to lower the conversion price was based on the company's future development prospects and stock price trends [2][18]. Group 2: Convertible Bond Details - The company issued 31.44 million convertible bonds with a total value of 314.404 million RMB, approved by the China Securities Regulatory Commission [8][9]. - The conversion period for these bonds started on December 3, 2020, and will end on May 27, 2026 [10]. - The conversion price has been adjusted multiple times in the past, with the most recent adjustment prior to this being to 12.00 RMB/share on July 8, 2025 [12][14]. Group 3: Shareholder Meeting - The third extraordinary general meeting of shareholders was held on August 14, 2025, where the proposal to adjust the conversion price was approved with over two-thirds of the voting rights in favor [21][33]. - A total of 605 shareholders participated in the meeting, representing 31.45% of the total shares [32]. - The voting results showed that 95.12% of the votes were in favor of the proposal, indicating strong support from shareholders [33].